February 23, 2019

Another Horizon 2020 Seal of Excellence for MultiplexDX from European Commission

We would like to proudly announce that MultiplexDX has received another Seal of Excellence certificate for their latest SME Instrument Horizon 2020 phase 2 proposal. The Seal of Excellence is considered to be the highest quality label and identifies the most innovative EU proposals. The Multiplex9+ project succeeded in passing all criteria such as innovation, commercialization strategy, team and business plan; however, it could not be funded due to budget limits. The proposal was evaluated by an independent panel consisting of specialists/experts in the field of cancer diagnostics.

Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:

“The Seal of Excellence is confirmation that there is a great innovative potential of our company, of our breast cancer diagnostic test called Multiplex9+. Our project was chosen among the top 10% of all EU proposals. The Seal of Excellence is analogous “to playing in the European Champions League” against the best projects in the EU and it feels great to be among the best of them. Now, we are just 0,3 points away from securing funding. I hope that the commitment and determination of our excellent team will soon be rewarded by an SME phase 2 grant.”

Our Multiplex9+ proposal is the highest scored project of all Slovak applicants in SME Instrument Horizon 2020 phase 2. Another “Seal of Excellence” and high score of 13,50 is evidence that our project is heading in the right direction regarding funding as well as commercialization.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News